Liver cancer battle: which combo therapy wins?

NCT ID NCT07340502

Not yet recruiting Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two treatment combinations for advanced liver cancer that cannot be removed by surgery. One group gets TACE (a procedure that blocks blood flow to the tumor and delivers chemo directly) plus immunotherapy and a targeted drug. The other group gets HAIC (a continuous chemo infusion through a catheter) plus the same drugs. The goal is to see which approach works better and is safer. About 364 adults with newly diagnosed liver cancer will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PD-1 inhibitors and lenvatinib
What this could lead to: If this study shows HAIC is better than TACE for certain patients, it could lead to more effective, personalized treatment for advanced liver cancer.
What could go wrong: This is an observational study, not a randomized trial, so results may be less definitive. It is also early-stage, and the treatments have known side effects like fatigue, liver damage, and bleeding risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC

More trials for these conditions

Other studies related to the condition(s) this trial covers.